Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
14.4M
-
Number of holders
-
113
-
Total 13F shares, excl. options
-
13.2M
-
Shares change
-
-128K
-
Total reported value, excl. options
-
$335M
-
Value change
-
-$3.27M
-
Put/Call ratio
-
1.85
-
Number of buys
-
48
-
Number of sells
-
-60
-
Price
-
$25.33
Significant Holders of Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) as of Q2 2024
128 filings reported holding ANIK - Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share as of Q2 2024.
Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) has 113 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.2M shares
of 14.4M outstanding shares and own 91.78% of the company stock.
Largest 10 shareholders include Trigran Investments, Inc. (2.14M shares), BlackRock Inc. (1.61M shares), Caligan Partners LP (1.44M shares), VANGUARD GROUP INC (790K shares), DIMENSIONAL FUND ADVISORS LP (749K shares), RENAISSANCE TECHNOLOGIES LLC (598K shares), MORGAN STANLEY (502K shares), BOOTHBAY FUND MANAGEMENT, LLC (502K shares), ACADIAN ASSET MANAGEMENT LLC (443K shares), and GEODE CAPITAL MANAGEMENT, LLC (341K shares).
This table shows the top 113 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.